Fig. 1From: Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experiencePattern of monthly headache days over three months of CGRP-mAb therapy. A In Super-Responders and Non-Responders. B In patients with and without concomitant depression. NR were significantly more likely to have concomitant depressionBack to article page